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Carboxylic ester antagonists of 1K,25-dihydroxyvitamin D3 show
cell-speci¢c actions
Michaela Herdick 1, Andreas Steinmeyer 2 and Carsten Carlberg 1
Background: The nuclear hormone 1K,25-dihydroxyvitamin D3 (1K,25(OH)2D3)
acts through the transcription factor vitamin D receptor (1K,25(OH)2D3 receptor,
VDR) via combined contact with the retinoid X receptor (RXR), coactivator
proteins and speci¢c DNA binding sites (1K,25(OH)2D3 response elements,
VDREs). Ligand-mediated conformational changes of the VDR are the basis of
the molecular mechanisms of nuclear 1K,25(OH)2D3 signaling. Cell-speci¢c VDR
antagonists would allow to dissect and ¢ne regulate the pleiotropic 1K,25(OH)2D3
endocrine system affecting the regulation of calcium homeostasis, bone
mineralization and other cellular functions.
Results: Two carboxylic ester analogues of 1K,25(OH)2D3, ZK159222 and
ZK168281, which have additional cyclopropyl rings and allylic alcohol
substructures in their side chain, were characterized in different 1K,25(OH)2D3
target tissues as functional antagonists of 1K,25(OH)2D3 signaling. In all tested
systems, ZK168281 showed lower residual agonistic activity and higher
antagonistic effects than ZK159222, but the strength of these effects was cell-
speci¢c. Both antagonists were shown to act via the same mechanisms: they
selectively stabilize an antagonistic conformation of the ligand-binding domain of
the VDR within VDR^RXR^VDRE complexes, which then inhibits the interaction
of the VDR with coactivator proteins and an induction of transactivation.
Interestingly, cells that have been treated with antagonists were found to contain
VDR^RXR heterodimers in a different conformation than cells that were
stimulated with an agonist. Moreover, the strength of the functional antagonism of
ZK159222 and ZK168281 appears to depend on the VDR/RXR expression ratio
and high RXR levels were found to reduce the antagonistic effect of both
compounds. In support of this observation, the overexpression of an
transactivation function 2 (AF-2) deletion mutant of RXR resulted for both
ZK159222 and ZK168281 in a reduced agonistic activity and an increased
antagonistic effect.
Conclusions: A novel, more potent VDR antagonist, ZK168281, was identi¢ed,
which stabilizes VDR^RXR heterodimers in living cells in a different conformation
than agonists. In addition, the VDR/RXR ratio was found as the major
discriminating factor for understanding cell-speci¢c effects of VDR antagonists.
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Introduction
The nuclear hormone 1K,25-dihydroxyvitamin D3
(1K,25(OH)2D3) mainly regulates calcium homeostasis
and bone mineralization [1], but also plays a role in con-
trolling cellular growth, differentiation and apoptosis [2].
Various analogues of 1K,25(OH)2D3, which mainly contain
modi¢cations of the side chain, have been developed with
the goal to improve the biological pro¢le of the natural
hormone for a potential therapeutic application [3]. Nearly
all of the approximately 2000 presently known
1K,25(OH)2D3 analogues have been characterized as
more or less potent agonists of the 1K,25(OH)2D3 receptor
(VDR) [4], which is a member of the nuclear receptor tran-
scription factor superfamily [5]. For other members of the
superfamily, such as the estrogen receptor (ER), the pro-
gesterone receptor (PR) and the retinoic acid receptor
(RAR), synthetic antagonists are known for a while [6],
whereas only two types of VDR antagonists, the 25-carbox-
ylic ester ZK159222 from Schering [7,8] and the 26,23-
lactone TEI-9647 from Teijin [9,10], have been described.
The VDR acts preferentially as a heterodimer with the
retinoid X receptor (RXR) [4] on speci¢c DNA sequences
in promoter regions of 1K,25(OH)2D3 target genes, re-
ferred to as 1K,25(OH)2D3 response elements (VDREs)
[11]. Simple VDREs consist of two hexameric nuclear re-
ceptor-binding sites, which are commonly arranged as a
direct repeat with three spacing nucleotides (DR3-type
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VDREs) [11]. The VDR contains a DNA-binding domain
(DBD), which is formed by two zinc-¢nger motifs that are
characteristic for the nuclear receptor superfamily [12], and
a ligand-binding domain (LBD) that is formed by 12 K-
helical structures, of which the last one, helix 12, contains a
short transactivation function 2 (AF-2) domain [13]. VDR^
RXR^VDRE complexes are the molecular core of DNA-
dependent 1K,25(OH)2D3 signaling [14] and the induction
of a conformational change within the LBD of the VDR by
interaction with 1K,25(OH)2D3 or its analogues is the most
critical step in this signaling process. The major conse-
quences of an agonist-induced conformational change of
the VDR are an induction of the dissociation of corepressor
proteins, such as NCoR and Alien [15], an enhancement of
the interaction with RXR (and consequently an increased
amount of complex formation with a VDRE [16]) and a
stimulation of the interaction with coactivator proteins of
the p160-family, such as SRC-1, transcriptional intermedi-
ary factor 2 (TIF2) and RAC3, via the AF-2 domain [17].
The AF-2 domain was described to be repositioned after
ligand binding to the LBD [13] and provides together with
amino acids of helices 3 and 5 an interface for the binding
of coactivators [18].
The two presently known VDR antagonists appear to act
via different mechanisms: TEI-9647 decreases the amount
of VDR^RXR heterodimer complex formation [10], where-
as ZK168281 is not able to promote an interaction of the
VDR with coactivator proteins of the p160-family neither
in solution nor in a complex with RXR on DNA [7]. A
comparison of the crystal structure of agonist- and antago-
nist-bound ER suggests that antagonists block AF-2 func-
tion by disrupting the topography of the AF-2 surface [19].
This mechanism of incorrect positioning and blocking of
the AF-2 domain has also been suggested for other nuclear
receptors [20^22]. Several of these antagonists, such as the
partial ER antagonist tamoxifen, show cell-speci¢c effects
as extreme as a shift from antagonism to agonism [23]. For
a potential therapeutic application of antagonists a descrip-
tion and understanding of such cell-speci¢c effects is
highly important.
In this study, a structural relative of ZK159222, ZK168281,
is described as a novel, more potent VDR antagonist. The
two compounds showed the same mechanism of action and
their functional antagonism was found to be cell-speci¢c.
The VDR/RXR ratio was found as the major discriminating
factor for understanding this cell speci¢city.
Results
Antagonistic and agonistic effects of the carboxylic ester
1K,25(OH)2D3 analogues (ZK159222 and ZK168281, for
structures see Figure 1) were compared in Cos-7 (SV40-
transformed African Green monkey kidney), Saos-2 (hu-
man osteogenic sarcoma), HaCaT (human immortalized
keratinocytes) or MCF-7 (human breast cancer) cells by
applying a saturating concentration of 1K,25(OH)2D3 (10
nM) alone or in combination with ZK159222 or ZK168281
at a 100-fold higher concentration (1 WM). Reporter gene
assays resulted for all four cell lines in a comparable in-
duction pattern of luciferase activity: 10 nM of the natural
hormone provided maximal induction, 1 WM of ZK159222
and ZK168281 reached only 3^40% of this value and the
combination of 1K,25(OH)2D3 with ZK159222 or
ZK168281 provided 20^60% of the maximal level, i.e.
both compounds show a clear antagonistic effect (Figure
2). In all tested cell lines the residual agonistic effect of
ZK168281 was found to be lower than that of ZK159222
and the corresponding antagonistic effect of ZK168281 was
higher than that of ZK159222, thus ZK168281 appears to
be a more effective antagonist than ZK159222. Interest-
Figure 1. Structure of 1K,25(OH)2D3 and its antagonistic
analogues. ZK159222 and ZK168281 are carboxylic esters of
1K,25(OH)2D3.
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ingly, the effects of ZK159222 and ZK168281 differ be-
tween the tested cell lines. The residual agonistic effect
of ZK159222 and ZK168281 in MCF-7 cells (Figure 2D) is
signi¢cantly lower than in Cos-7 cells (Figure 2A), whereas
in HaCaT (Figure 2C) and Saos-2 (Figure 2B) cells ago-
nistic activities between these extremes were observed.
The corresponding antagonistic effect in the different
cell lines showed the same ranking, i.e. the antagonism
of both compounds is higher in MCF-7 than in Cos-7 cells.
Taken together, both analogues act as functional antago-
nists of 1K,25(OH)2D3, but the strength of their antago-
nism is cell-speci¢c.
For a more detailed investigation, the two VDR antago-
nists were analyzed ¢rst in a series of assays with in vitro
translated receptors (Figure 3). The stabilization of VDR
conformations by 1K,25(OH)2D3, ZK159222 and
ZK168281 was analyzed by limited protease digestion
(LPD) assays using the endoprotease chymotrypsin. As
shown previously with LPD assays using trypsin
[16,24,25], also chymotrypsin provided up to three diges-
tion products (Figure 3A). These three VDR fragments
contain major parts of the LBD and are interpreted as
the functional VDR conformations 1, 2 and 3 that mediate
the agonistic (c1LPD) [17], the antagonistic (c2LPD) [7] and
the non-agonistic (c3LPD) [26] action of the receptor. The
natural hormone stabilized 35% of all VDR molecules in
c1LPD and 10% in c3LPD, but no receptor molecules in
c2LPD. In contrast, ZK159222 and ZK168281 stabilized
only 1^4% of all VDR molecules in c1LPD, 10% in c2LPD
and 8^16% in c3LPD. In DNA-dependent LPD assays, i.e.
when VDR^RXR heterodimers are formed on the rat atrial
natriuretic factor (ANF) DR3-type VDRE, the absolute
amount of stabilized VDR molecules slightly increased,
but the ratio between the conformations stayed constant
(data not shown).
Gel shift assays were performed with in vitro translated
VDR^RXR heterodimers bound to the rat ANF DR3-
type VDRE in the presence of increasing amounts of glu-
tathione S-transferase (GST)-TIF2646ÿ926 fusion proteins
and saturating concentrations (10 WM) of 1K,25(OH)2D3,
ZK159222 and ZK168281 (Figure 3B). In the presence of
1K,25(OH)2D3, VDR^RXR^TIF2^VDRE complexes
(supershifts) were observed, whereas in the presence of
ZK159222 or ZK168281 no supershifts could be detected
even at high coactivator concentrations. This indicates that
both antagonists were not able to induce a change into the
agonistic VDR conformation (c1LPD), which would enable
an interaction with coactivator proteins. However, in the
absence of coactivators a comparable intensity (approxi-
mately 40% shifted probe) of dose-dependent VDR^
RXR heterodimer complex formation on DNA was ob-
served for 1K,25(OH)2D3, ZK159222 and ZK168281 (in
relation to 16% shifted probe with solvent).
Figure 2. Cell-speci¢c differences in functional antagonism.
Luciferase reporter gene assays were performed with extracts
from Cos-7 (A), Saos-2 (B), HaCaT (C) or MCF-7 (D) cells that
were transiently transfected with a luciferase reporter gene
construct driven by four copies of the rat ANF DR3-type VDRE
together with the expression vectors for VDR and RXR (each
1 Wg). Cells were treated for 16 h with indicated concentrations of
1K,25(OH)2D3, ZK159222 and ZK168281 alone or in combination.
Stimulation of normalized luciferase activity was calculated in
comparison to solvent-induced controls. The data are presented in
reference to maximal induction of reporter gene activity. Columns
represent the mean of triplicates and the bars indicate standard
deviation.
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Figure 3. In vitro characterization of ZK159222 and ZK168281. LPD assays (A) were performed by preincubating in vitro translated
35S-labelled VDR with saturating concentrations (10 WM) of 1K,25(OH)2D3, ZK159222 and ZK168281 (or solvent as a control). After
digestion with chymotrypsin, samples were electrophoresed through 15% SDS^polyacrylamide gels. Supershift experiments (B) were
performed with in vitro translated VDR^RXR heterodimers that were preincubated with increasing amounts of bacterially expressed
GST^TIF2646ÿ926 (1, 3 and 6 Wg), saturating concentrations (10 WM) of 1K,25(OH)2D3, ZK159222 and ZK168281 (or solvent as a control)
and the 32P-labelled rat ANF DR3-type VDRE. VDR^RXR heterodimers were separated from free probe through 8% non-denaturing
polyacrylamide gels. GSC experiments (C) were performed with in vitro translated VDR^RXR heterodimers that were preincubated with
saturating concentrations (10 WM) of 1K,25(OH)2D3, ZK159222 and ZK168281 (or solvent as a control). After digestion with chymotrypsin,
VDR^RXR heterodimer conformations were separated from free probe through 8% non-denaturing polyacrylamide gels. Representative
experiments are shown. The amount of ligand-stabilized VDR conformations 1 (c1LPD), 2 (c2LPD, only in case of ZK159222 and ZK168281)
and 3 (c3LPD) in relation to VDR input (A), of VDR-RXR-VDRE or VDR-RXR-VDRE-TIF2 (`supershift') complexes in relation to free probe
(B) and of DNA-complexed VDR^RXR heterodimer conformations 1 (c1GSC) and 2 (c2GSC) in relation to non-digested VDR^RXR^VDRE
complexes (C) was quanti¢ed by phosphorimaging. In all cases columns represent the mean of triplicates and the bars indicate standard
deviations.
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Gel shift clipping (GSC) assays were performed with in
vitro translated VDR^RXR heterodimers bound to the rat
ANF DR3-type VDRE in the presence of saturating con-
centrations (10 WM) of 1K,25(OH)2D3, ZK159222 and
ZK168281 (Figure 3C). After the digestion with chymo-
trypsin two VDR^RXR heterodimer conformations, re-
ferred to as c1GSC and c2GSC [26], could be discriminated.
Interestingly, the natural hormone stabilized 25% of all
DNA-binding VDR^RXR heterodimers in c1GSC (gel shift
assay as reference), whereas in the absence of ligand only
10% of the heterodimers were stabilized in c2GSC. Interest-
ingly, both antagonists also stabilized approximately 25% of
the pool of DNA-bound VDR^RXR heterodimers, but in
c2GSC, i.e. in a different conformation than observed with
VDR agonists. Taken together, both antagonists show in
these in vitro assays clear differences to the natural hor-
mone (as a representative agonist) concerning the stabiliza-
tion of speci¢c conformations of the VDR-LBD and the
whole VDR^RXR heterodimer complex, which then pre-
vents the interaction with coactivator proteins.
The next series of experiments, gel shift and GSC assays
with the rat ANF DR3-type VDRE, were performed with
nuclear extracts from Cos-7 and MCF-7 cells that overex-
pressed VDR and RXR (Figure 4). Before scraping, the
cells were preincubated with saturating concentrations of
1K,25(OH)2D3, ZK159222 and ZK168281 for 1 h, but in
the following assays no extra ligand was added. Gel shift
assays with nuclear extracts from Cos-7 cells (Figure 4A)
and MCF-7 cells (Figure 4B) provided the same protein^
DNA complexes than gel shift assays with in vitro trans-
lated VDR^RXR heterodimers. With Cos-7 nuclear ex-
tracts a clear ligand-dependent increase of VDR^RXR^
VDRE complex formation by 1K,25(OH)2D3 (sixfold in-
duction in comparison to solvent-treated cells) and by
ZK159222 and ZK168281 (threefold induction) was ob-
served, whereas with MCF-7 nuclear extracts no ligand
effect was found. Interestingly, GSC assays with nuclear
extracts (Figure 4C,D) also provided the same VDR^RXR
heterodimers conformations as in vitro translated material
(Figure 3C). Nuclear extracts from cells that have been
treated with the agonist 1K,25(OH)2D3 contain VDR^
RXR heterodimers in conformation c1GSC, whereas in cells
that have been treated with antagonists VDR^RXR heter-
odimers are in conformation c2GSC.
In contrast to MCF-7 cells and other 1K,25(OH)2D3 target
cells, Cos-7 cells do not express endogenous VDR and
only relatively low levels of endogenous RXR (data not
shown). This cell line is therefore well suited for analyzing
the effect of transiently overexpressed VDR, RXR and
TIF2 proteins on the antagonistic effect of ZK159222
and ZK168281 (Figure 5). Cos-7 cells were transfected
with varied amounts of expression vectors for VDR, RXR
and the coactivator TIF2 and then stimulated with saturat-
ing concentrations of 1K,25(OH)2D3 (10 nM) alone or in
combination with ZK159222 or ZK168281 at a 100-fold
higher concentration (1 WM). Reporter gene assays pro-
vided patterns of luciferase activity (Figure 5, for a better
comparison all patterns were normalized to respective max-
imal induction by 1K,25(OH)2D3) that are very comparable
to that presented in Figure 2A, i.e. ZK168281 showed a
lower agonistic activity and higher antagonistic effect than
ZK159222. The overexpression of increasing amounts of
both VDR and RXR (Figure 5A) as well as the overexpres-
sion of increasing amounts of TIF2 at a constant expres-
sion level of VDR and RXR (Figure 5B) showed no sig-
ni¢cant effect on the pattern. In contrast, overexpression of
increasing amounts of RXR at a constant, low expression
Figure 3 (continued)
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level of VDR (Figure 5C) resulted in a signi¢cant increase
of the agonistic activity of ZK159222 (and to a lower extent
also of ZK168281) and a respective decrease of the antag-
onistic effect (at higher RXR concentrations ZK159222
showed a signi¢cant antagonistic effect). Taken together,
the strength of the antagonistic effect of ZK159222 and
ZK168281 depends on the VDR/RXR expression ratio
and high RXR levels appear to reduce the antagonism of
both compounds.
In order to test the involvement of RXR in functional
antagonism of ZK159222 and ZK168281, the effect of
the overexpression of an AF-2 deletion mutant of RXR
(RXR444) in comparison to wild type RXR (RXRwt) was
tested in Cos-7 cells (Figure 6). The cells were transfected
with expression vectors for VDR, RXRwt or RXR444 and
then stimulated with saturating concentrations of
1K,25(OH)2D3 (10 nM) alone or in combination with
ZK159222 or ZK168281 at a 100-fold higher concentration
(1 WM). Reporter gene assays provided for VDR^RXRwt
heterodimers the usual luciferase activity patterns (com-
pare Figs. 2A and 5). Interestingly, the overexpression of
RXR444 and the following formation of VDR^RXR444
heterodimers resulted for antagonists in a reduced agonistic
activity and in an increased antagonistic effect. This obser-
vation suggests that RXRwt allows less of an antagonistic
effect for VDR^RXR heterodimers, when the VDR is oc-
cupied by ZK159222 or ZK168281. Alternatively, when
VDR is complexed with RXR444, the absence of the
AF-2 domain results in a heterodimer responding more
to the antagonistic actions of ZK159222 and ZK168281.
Discussion
Agonism and antagonism of natural and synthetic nuclear
hormones are closely related processes. Molecules that se-
lectively activate or inhibit a speci¢c nuclear receptor are
of considerable biological signi¢cance and may have impor-
tant clinical applications. In this study, a dihomo derivative
of the recently identi¢ed VDR antagonist ZK159222 [7,8]
was characterized in different 1K,25(OH)2D3 target tissues
as a novel functional antagonist. Both antagonists are able
to stabilize the same amount of VDR^RXR heterodimers
on DNA as the natural hormone, which indicates that in
contrast to the 26,23-lactone antagonist the inhibition of
VDR^RXR^VDRE complex formation is not a mechanism
of action of carboxylic ester antagonists. A direct compar-
Figure 4. Ligand-responsiveness of VDR^
RXR heterodimers in living cells. Gel shift
(A, B) and GSC experiments (C, D) were
performed with nuclear extracts from VDR-
and RXR-overexpressing Cos-7 (A, C) and
MCF-7 (B, D) cells were preincubated with
saturating concentrations (100 nM) of
1K,25(OH)2D3, ZK159222 and ZK168281
(or solvent as a control). For GSC assays
samples were digested with trypsin. In
both cases protein^DNA complexes were
separated from free probe through 8%
non-denaturing polyacrylamide gels.
Representative experiments are shown.
The amount of DNA-complexed VDR^RXR
heterodimers (A, B) and of VDR^RXR
heterodimer conformations 1 (c1GSC) and
2 (c2GSC) in relation to non-digested VDR^
RXR^VDRE complexes (C, D) was
quanti¢ed by phosphorimaging. Columns
represent the mean of triplicates and the
bars indicate standard deviation.
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ison of the functional antagonism of ZK159222 and
ZK168281 in different cell lines indicated that ZK168281
is more potent, since it shows lower residual agonistic ac-
tivity and a higher antagonistic effect. Moreover,
ZK168281 provides functional antagonism already at ap-
proximately three times lower concentrations than
ZK159222, which is also indicated by respective lower
half maximal activation (EC50) values in in vitro assays
[27].
Both carboxylic ester antagonists function via the same
mechanism as they selectively stabilize an antagonistic
conformation (c2LPD) of the VDR^LBD, which is not ob-
served with VDR agonists. The observation that ZK159222
and ZK168281 cannot induce supershifts with TIF2 sug-
gests that in this antagonistic conformation helix 12 of the
LBD appears to be not positioned correctly, so that the
AF-2 domain on this helix is not able to interact with
the LXXLL (L = leucine, X = any amino acid) core nuclear
receptor interaction motifs of coactivator proteins [19,21].
This lack of interaction with coactivators may be the main
reason why ZK159222 and ZK168281 stimulate only resid-
ual agonistic activity.
GSC assays with the endoprotease chymotrypsin allowed
for the ¢rst time a visualization of different conformations
representing antagonist-complexed VDR^RXR hetero-
dimers (c2GSC) and agonist-complexed VDR^RXR hetero-
dimers (c1GSC). Interestingly, these different heterodimer
conformations can not only be observed with receptors that
were translated in vitro, but also with receptor complexes
within nuclear extracts from different agonist- and antago-
nist-treated cells. This observation con¢rms that antago-
nist-speci¢c conformations also exist in living cells, i.e.
that an in vitro evaluation of antagonistic receptor confor-
mations represents the in vivo situation. Therefore, GSC
assays with nuclear extracts appear to be very appropriate
for screening a larger group of 1K,25(OH)2D3 analogues
and different cell lines or tissues for potential antagonists.
Cell-speci¢c differences in the residual agonism of
ZK159222 and ZK168281 appear to be largely related to
the ratio of the expression levels of RXR and VDR. The
agonistic activity of the VDR antagonists appears to in-
crease, when the amount of RXR protein is in excess to
VDR protein, whereas it decreases, when an AF-2 deletion
mutant of RXR (RXR444) is overexpressed. This suggests
Figure 4 (continued).
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that the partner receptor RXR, in particular its AF-2 do-
main, has a reasonable contribution to the agonistic activity
of VDR^RXR heterodimers. It has been suggested for
RAR^RXR heterodimers that the AF-2 domain of RXR
mimics the LXXLL nuclear receptor interaction motif of
coactivators and interacts in the absence of ligand with the
AF-2 domain of RAR [28]. It may therefore be possible
that the RXR AF-2 domain modulates the orientation of
the VDR AF-2 domain, so that despite an antagonist bind-
ing a reasonable proportion of the VDR molecules shifts
into the agonistic conformation. In addition, even in the
absence of RXR ligands the RXR AF-2 domain may be
able to contact coactivators. Both possibilities would in-
crease the agonistic activity of antagonist-bound VDR^
RXR heterodimers and may explain the modulatory effect
of RXR expression levels. Each tissue or cell line can be
assumed to have its individual expression level for VDR
and RXR. MCF-7 cells have a relatively high VDR/RXR
ratio (data not shown) and therefore provide a low agonistic
activity of antagonists, whereas Cos-7 cells are known for
their low VDR/RXR ratio, which results in a high agonistic
Figure 6. The impact of the AF-2 domain of RXR on functional
antagonism. Luciferase reporter gene assays were performed with
extracts from Cos-7 cells that were transiently transfected with a
luciferase reporter gene construct driven by four copies of the rat
ANF DR3-type VDRE together with indicated amounts of
expression vectors for VDR, RXRwt or RXR444. Cells were
treated for 16 h with indicated concentrations of 1K,25(OH)2D3,
ZK159222 and ZK168281 alone or in combination. Stimulation of
normalized luciferase activity was calculated in comparison to
solvent-induced controls. The data are presented in reference to
maximal induction of reporter gene activity. Columns represent the
mean of triplicates and the bars indicate standard deviations.
Figure 5. Functional antagonism at different VDR, RXR and TIF2
expression levels. Luciferase reporter gene assays were
performed with extracts from Cos-7 cells that were transiently
transfected with a luciferase reporter gene construct driven by
four copies of the rat ANF DR3-type VDRE together with
indicated amounts of expression vectors for VDR, RXR and TIF2.
In different experimental series VDR and RXR were increased in
parallel (A), TIF2 was increased at constant amounts of VDR and
RXR (B) and RXR was increased at constant amounts of VDR
(C). Cells were treated for 16 h with indicated concentrations of
1K,25(OH)2D3, ZK159222 and ZK168281 alone or in combination.
Stimulation of normalized luciferase activity was calculated in
comparison to solvent-induced controls. The data are presented in
reference to maximal induction of reporter gene activity. Columns
represent the mean of triplicates and the bars indicate standard
deviation. A statistically signi¢cant (P6 0.02 according to
Student's t-test) reduction of reporter gene activity in reference to
the activity induced by 100 nM 1K,25(OH)2D3 is indicated by
asterisks.
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activity. Taken together, the fact that VDR preferentially
forms heterodimers with RXR [4], whereas ER and PR
each form homodimers [29], appears to result in different
mechanisms for the cell-speci¢c action of VDR antagonists
versus ER or PR antagonists.
Signi¢cance
The nuclear hormone 1K,25(OH)2D3 exerts pleiotropic ac-
tivities such as the regulation of calcium homeostasis, bone
mineralization, cellular growth, differentiation and apopto-
sis. Approximately 2000 1K,25(OH)2D3 analogues are pres-
ently known as agonists of the transcription factor VDR,
but only the 25-carboxylic ester analogue (ZK159222) and
a 26,23-lactone analogue (TEI-9647) were identi¢ed as
VDR antagonists. In this study, a second carboxylic ester
analogue (ZK168281) was characterized in different
1K,25(OH)2D3 target cells as a novel, more potent VDR
antagonist. The strength of the functional antagonism of
both carboxylic ester analogues was found to be cell-spe-
ci¢c. The ratio of VDR/RXR expression was found to be
the major discriminating factor for understanding this cell
speci¢city. Both carboxylic ester analogues selectively sta-
bilize an antagonistic conformation of the LBD of VDR
within VDR^RXR heterodimers, which inhibits the inter-
action of the VDR with coactivator proteins and an induc-
tion of transactivation. Notably, the antagonistic conforma-
tion of VDR^RXR heterodimers could also be observed in
nuclear extracts from ligand-treated cells and will allow a
screening for further VDR antagonists.
Materials and methods
Compounds
ZK159222 [8] and ZK168281 are carboxylic esters of 1K,25(OH)2D3 and
were both synthesized at the Medicinal Chemistry Department at Scher-
ing AG. The structures of both compounds are shown in Figure 1.
ZK168281 is formally derived from ZK159222 by introduction of an eth-
ylene unit between carbon 25 and the ester moiety. The ester side chain
itself is shortened by two carbon atoms, thus providing a total side chain
length that equals that of ZK159222. All compounds were dissolved in
2-propanol; further dilutions were made in DMSO (for in vitro assays) or
in ethanol (for cell culture assays).
DNA constructs
Mammalian expression constructs. The full-length cDNAs for hu-
man VDR [30], human RXRK [31] and human TIF2 [32] were subcloned
into the SV40 promoter-driven pSG5 expression vector (Stratagene,
Heidelberg, Germany). The AF-2 deletion mutant of RXR (RXR444)
was generated by introducing a stop codon at amino acid position
444 [33].
VDRE-driven reporter gene construct. Four copies of the DR3-type
VDRE from the rat ANF gene promoter [34] were fused with the thymi-
dine kinase (tk) minimal promoter driving the luciferase reporter gene.
GST fusion protein construct. The nuclear receptor interaction do-
main human TIF2 (spanning from amino acid 646 to 926) [32] was
subcloned into the GST fusion vector pGEX (Amersham-Pharmacia,
Freiburg, Germany).
In vitro protein translation, bacterial protein overexpression and
nuclear extracts
In vitro translated VDR and RXR proteins were generated by transcrib-
ing their respective linearized pSG5-based cDNA expression vector with
T7 RNA polymerase and translating these RNAs in vitro using rabbit
reticulocyte lysate as recommended by the supplier (Promega, Mann-
heim, Germany). Bacterial overexpression of GST^TIF2646ÿ926 was fa-
cilitated in the Escherichia coli BL21(DE3)pLysS strain (Stratagene) by
induction with isopropyl-L-D-thio-galactopyranoside (0.25 mM) for 3 h at
37³C. For the generation of nuclear extracts, Cos-7 cells were trans-
fected with pSG5-based cDNA expression vectors for VDR and RXR
and stimulated for 1 h with ligand. Cells were then collected and nuclear
extracts were prepared as described [35].
LPD assay
In vitro translated, 35S-labelled VDR protein (2.5 Wl) was incubated with
ligand for 15 min at room temperature in 20 Wl binding buffer (10 mM
HEPES [pH 7.9], 1 mM DTT, 0.2 Wg/Wl poly(dI-C) and 5% glycerol). The
buffer was adjusted to 150 mM of monovalent cations by addition of KCl.
Chymotrypsin (Roche Diagnostics, Mannheim, Germany, ¢nal concen-
tration 16.7 ng/Wl) was then added and the mixtures were further incu-
bated for 10 min at room temperature. The digestion reactions were
stopped by adding 25 Wl protein gel loading buffer (0.25 M Tris, pH
6.8, 20% glycerol, 5% mercaptoethanol, 2% SDS, 0.025% bromophenol
blue). The samples were denatured at 85³C for 3 min and electropho-
resed through a 15% SDS^polyacrylamide gel. The gels were dried and
exposed to a Fuji MP2040S imager screen. The individual protease-
sensitive VDR fragments were quanti¢ed on a Fuji FLA2000 reader
(Tokyo, Japan) using Image Gauge software (Raytest, Sprockhoëvel,
Germany).
Gel shift, supershift and GSC assay
In vitro translated VDR^RXR heterodimers (approximately 20 ng speci¢c
protein) were incubated with ligand for 15 min at room temperature in a
total volume of 20 Wl binding buffer, whereas nuclear extracts (5 Wg total
protein) were not pretreated with ligand. In both cases the buffer was
adjusted to 150 mM by addition of KCl. For supershift assays, approx-
imately 3 Wg of bacterially expressed GST-TIF2646ÿ926 fusion protein
were included in the incubation. Approximately 1 ng of the 32P-labelled
rat ANF DR3-type VDRE (50 000 cpm) was then added and incubation
was continued for 20 min. For GSC assays, the endoprotease chymo-
trypsin (Roche Diagnostics) was added to a ¢nal concentration of 16.7
ng/Wl and the incubation was continued for 30 min at room temperature.
Protein^DNA complexes were resolved through 8% non-denaturing
polyacrylamide gels in 0.5UTBE (45 mM Tris, 45 mM boric acid,
1 mM EDTA, pH 8.3) and were quanti¢ed on a Fuji FLA2000 reader.
Transfection and luciferase assays
Cos-7 SV40-transformed African Green monkey kidney cells, Saos-2
human osteogenic sarcoma cells, HaCaT human immortalized keratino-
cytes or MCF-7 human breast cancer cells were seeded into 6-well
plates (105 cells/ml) and grown overnight in phenol red-free DMEM
supplemented with 10% charcoal-treated fetal bovine serum (FBS).
Liposomes were formed by incubating 1 Wg of the reporter plasmid
and indicated amounts of pSG5-based receptor expression vectors for
VDR, RXR and TIF2 with 15 Wg N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-tri-
methylammonium methylsulfate (DOTAP, Roth, Karlsruhe, Germany, 20
Wg for HaCaT cells) for 15 min at room temperature in a total volume of
100 Wl. After dilution with 900 Wl phenol red-free DMEM, the liposomes
were added to the cells. Phenol red-free DMEM supplemented with 30%
charcoal-treated FBS (500 Wl) was added 4 h after transfection. At this
time, ligands were also added. The cells were lysed 16 h after onset of
stimulation using the reporter gene lysis buffer (Roche Diagnostics) and
the constant light signal luciferase reporter gene assay was performed
as recommended by the supplier (Canberra-Packard, Dreieich, Ger-
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Research Paper Cell-speci¢c action of VDR antagonists Herdick et al. 893
many). The luciferase activities were normalized with respect to protein
concentration and induction factors were calculated as the ratio of lucif-
erase activity of ligand-stimulated cells to that of solvent controls.
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